Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
The top analyst upgrades, downgrades and other research calls from Wednesday include Abercrombie & Fitch, Amgen, Electronic Arts, General Motors, Goldcorp, Shopify, 3D Systems and Under Armour.
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
CytomX Therapeutics shares made a solid gain in Wednesday’s session following announcement of a strategic collaboration with Amgen in immuno-oncology.
Chris Lange AbbVie shares made a handy gain on Thursday after it was announced that the company resolved its Humira patent disputes with Amgen.
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
